Breaking News, Financial News

Financial Report: Johnson & Johnson 3Q

Worldwide Pharmaceutical sales were $5.5 billion in the quarter (+5%), with operational growth of 6% and a negative impact from currency of 1%.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Johnson & Johnson 3Q 3Q Revenues: $15.0 billion (-1%) 3Q Earnings: $3.4 billion (+2%) YTD Revenue: $45.9 billion (+1%) YTD Earnings: $11.4 billion (+13%) Comments: Worldwide Pharmaceutical sales were $5.5 billion in the quarter (+5%), with operational growth of 6% and a negative impact from currency of 1%. Domestic and international sales were up 7% and 2%, respectively. Remicade sales were $1.2 billion in the quarter (+19%). Prezista sales were $230 million (+52%). Risperdal ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters